Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evaxion Biotech ( (EVAX) ) just unveiled an announcement.
Evaxion A/S, a clinical-stage TechBio company listed on Nasdaq and headquartered in Denmark, develops AI-Immunology powered vaccines for cancer and infectious diseases using a proprietary artificial intelligence platform. Its more than 40-strong team spans from target discovery to clinical development, advancing a pipeline of both personalized and off-the-shelf cancer vaccines alongside prophylactic vaccine candidates that seek to address high unmet medical needs.
On March 19, 2026, Evaxion announced that it has convened its Annual General Meeting to be held on April 16, 2026, at its offices in Hørsholm, Denmark, with the agenda and related proposals made available on the company’s website. The notice underscores routine corporate governance for the AI-driven vaccine developer, giving shareholders a formal venue next month to review strategic progress, weigh in on proposals and maintain oversight of a business operating at the convergence of biotechnology and artificial intelligence.
The most recent analyst rating on (EVAX) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
The score is driven primarily by improved capitalization but still-weak cash generation and profitability. Technicals are moderately favorable with improving momentum, while valuation remains limited by losses. Earnings-call commentary adds support via clear milestone roadmap, strong EVX-01 results, and runway into H2 2027, tempered by dilution/partnering execution risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a Denmark-based, clinical-stage TechBio company that develops novel vaccines using its proprietary, clinically validated AI-Immunology platform. The technology applies artificial intelligence to decode the human immune system, supporting rapid target discovery, drug design and development for both personalized and off-the-shelf cancer vaccines, as well as prophylactic vaccines for infectious diseases addressing high unmet medical needs.
With a team of more than 40 specialists covering the full value chain from target discovery through clinical development, Evaxion has built a pipeline of vaccine candidates aimed at transforming patient care. The company is listed on Nasdaq under the ticker EVAX and positions itself at the intersection of biotechnology and AI-driven drug discovery, targeting global markets for oncology and infectious disease therapies.
Average Trading Volume: 57,426
Technical Sentiment Signal: Sell
Current Market Cap: $31.53M
See more data about EVAX stock on TipRanks’ Stock Analysis page.